FFOX - ETF AI Analysis
Top Page
FundX Future Fund Opportunities ETF (FFOX)
FFOX vs. SPDR S&P 500 ETF (SPY)
- AUM
- 236.72M
- Region
- North America
- Expense Ratio
- 1.02%
- Beta
- 0.97
- Issuer
- FundX
- Inception Date
- Jun 10, 2025
- Dividend Yield
- 1.77%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
FFOX Summary
The FundX Future Fund Opportunities ETF (FFOX) is an actively managed fund that looks for “future-focused” themes instead of tracking a set index. It mainly invests in smaller U.S. companies tied to big trends like new technology, health care innovation, and changing consumer habits. Some of its well-known holdings include Guardant Health and Natera. An investor might choose this ETF for growth potential and diversification across several forward-looking industries. However, because it focuses on smaller, trend-driven companies and doesn’t follow a broad market index, its price can be more volatile and may go up and down sharply.
How much will it cost me?
The FundX Future Fund Opportunities ETF (FFOX) has an expense ratio of 1.00%, meaning you’ll pay $10 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying and investing in sectors aligned with transformative global trends.
What would affect this ETF?
FFOX's focus on transformative megatrends like technology and healthcare positions it to benefit from advancements in innovation and demographic shifts, which could drive long-term growth. However, its exposure to small- and mid-cap companies may make it more sensitive to economic downturns or interest rate hikes, which can negatively impact these sectors. Additionally, regulatory changes in healthcare or technology could pose risks to its top holdings.
FFOX Top 10 Holdings
FFOX is leaning into future-focused themes, with rising names like Natera and Guardant Health helping to power its health care tilt, while Halozyme adds steady support despite some technical headwinds. On the tech side, Ciena and SiTime have been climbing, giving the fund a lift from networking and semiconductor-adjacent plays, even as InterDigital and Ligand Pharma show more mixed, stop-and-go momentum. Overall, the ETF is clearly concentrated in U.S.-based technology and health care innovators, making it a bet on smaller, fast-changing growth stories rather than broad market stability.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NTRA | Natera | 3.43% | $8.12M | $59.72B | 114.42% | 73Outperform |
 GH | Guardant Health | 3.24% | $7.67M | $23.99B | 93.49% | 61Neutral |
 HALO | Halozyme | 2.80% | $6.63M | $14.86B | 102.55% | 73Outperform |
 LGND | Ligand Pharma | 2.04% | $4.84M | $6.43B | 72.54% | 60Neutral |
 IDCC | InterDigital | 2.02% | $4.79M | $8.02B | -21.39% | 76Outperform |
 GMED | Globus Medical | 2.02% | $4.78M | $10.48B | 28.54% | 82Outperform |
 HRI | Herc Holdings | 1.91% | $4.53M | $5.55B | 20.69% | 67Neutral |
 LFUS | Littelfuse | 1.90% | $4.51M | $9.99B | 61.88% | 76Outperform |
 QTWO | Q2 Holdings | 1.80% | $4.26M | $4.14B | 10.26% | 75Outperform |
FFOX Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFOX, the sentiment is Negative. The current price of 27.94 is below the 20-day moving average (MA) of 28.29, below the 50-day MA of 28.62, and below the 200-day MA of 28.61, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of 71.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FFOX.
FFOX Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FFOX | $27.94 | $30.00(7.38% Upside) | $236.72M | 1.02% | 67Neutral |
 FEPI | $38.58 | $51.12(32.50% Upside) | $717.23M | 0.65% | 71Outperform |
 AIPI | $33.76 | $46.64(38.16% Upside) | $478.04M | 0.65% | 73Outperform |
 DUNK | $28.16 | $35.78(27.04% Upside) | $174.87M | 0.75% | 71Outperform |
 GPTY | $36.66 | $51.09(39.35% Upside) | $132.04M | 1.06% | 67Neutral |
 CEPI | $26.99 | $46.35(71.73% Upside) | $119.27M | 0.85% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FFOX | FundX Future Fund Opportunities ETF | 27.94 | 0.27 | 0.97% | |
| FEPI | REX FANG & Innovation Equity Premium Income ETF | 38.58 | 0.45 | 1.17% | |
| AIPI | REX AI Equity Premium Income ETF | 33.76 | 2.21 | 7.01% | |
| DUNK | Dana Unconstrained Equity ETF | 28.16 | 2.13 | 8.17% | |
| GPTY | YieldMax AI & Tech Portfolio Option Income ETF | 36.66 | 2.56 | 7.52% | |
| CEPI | REX Crypto Equity Premium Income ETF | 26.99 | -0.72 | -2.61% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.